

# Market Announcement

25 November 2025

---

## Pathkey.AI Ltd (ASX: PKY) – Trading Halt

Trading in the securities of Pathkey.AI Ltd ('PKY') will be halted at the request of PKY, pending the release of an announcement by PKY.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Thursday, 27 November 2025; or
- the release of the announcement to the market.

PKY's request for a trading halt is attached below for the information of the market.

### Issued by

ASX Compliance



25 November 2025

Ms Vanessa Nevjestic  
Manager, Listings Compliance (Perth)  
ASX Compliance Pty Ltd

Dear Vanessa

### **TRADING HALT REQUEST**

**PathKey.AI Ltd (ASX: PKY)** (the "Company") requests that the securities of the Company be placed into a trading halt of up to two trading days with immediate effect.

For the purposes of ASX Listing Rule 17.1 and in support of its request, the Company advises that:

1. The trading halt is requested for the purposes of considering, planning and executing a capital raising.
2. The Company requests that the trading halt remains in place until the earlier of the Company releasing an announcement regarding the capital raising or prior to the commencement of trading on Thursday, 27 November 2025.
3. The Company is not aware of any reason why the request for the trading halt should not be granted or any other information necessary to inform the market about the trading halt.

This announcement was authorised by the Board of PKY.

### **About Pathkey.AI**

Pathkey.AI Limited (ASX: PKY) is an Australian technology company applying artificial intelligence to improve the efficiency, success, and transparency of clinical trials. Pathkey.AI's core platform, TrialKey, is an AI-powered decision-support tool that predicts the probability of success for clinical trials and helps sponsors optimise trial design and planning. The company is committed to transforming drug development by reducing risk, improving resource allocation and unlocking data-driven innovation across the life sciences sector